


To Financial Editors:
【For Immediate Release】



TUL Obtained Products Approval for Two New Eye Drops Products

【13 November 2009 - Hong Kong】 - The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC, is pleased to announce that the Group has obtained official production approval for two new OTC eye drops products from the State Food and Drug Administration of the PRC. The two products are Bendazac Lysine Eye Drops and Compound Chondroitin Sulfate Eye Drops. The Bendazac Lysine Eye Drops product is used in the prevention and treatment of early senile cataract. Market data shows rapid market sales growth of the product in the past two years. The Compound Chondroitin Sulfate Eye Drops product is mainly for the prevention and treatment of eye fatigue and dry eyes. Statistics show a compound growth rate of over 30% in the market sales since 2001. The market generally expects that the demand for the two products will be continuous and strong in the coming years.

Mr. Choy Kam Lok, Chairman of TUL said, “The Group is pleased to obtain the production approval for the two eye drops products. TUL has been striving to research and develop new products of both high quality and high market demand. Within this year, we obtained approval for Rimantadine Hydrochloride Granules that is suitable for the prevention and treatment of influenza virus type A, and launched the exclusive new OTC medicine Acetaminophen and Dextromethorphan Hydrobromide Oral Solution that is specifically used for the treatment of influenza and cough. We aimed at getting more new medicines launched to the market soon and increasing the market share of TUL branded products.”

- End -

About The United Laboratories International Holdings Limited

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 30 June 2009, the Group has a total of 168 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong. 76 were in production, and 34 were listed in Insurance Catalogue. 12 finished products are in the list of National Basic Drugs Catalogue. For more information about TUL, please visit the company’s website at www.tul.com.hk.

Issued by Creativeline Communications for and on behalf of The United Laboratories International Holdings Limited. For further information, please contact:

Creativeline Communications

Mr. Wayne Chau / Ms. Sylvia Lau

Tel: (852) 2730 6212 / 6390 9406

Fax: (852) 2736 0745

Email: wayne@creativeline.com.hk / sylvia@creativeline.com.hk